CA
AARD

Cliff Asness’s Aardvark Therapeutics AARD Stock Holding History

Cliff Asness’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.77M Buy
480,249
+345,754
+257% +$1.62M ﹤0.01% 2400
2026
Q1 		$507K Buy
+134,495
New +$1.39M ﹤0.01% 3114

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cliff Asness's AARD Position: Q2 2026 in Review

Cliff Asness increased its Aardvark Therapeutics (AARD) stake by 257% in Q2 2026, buying an estimated $1.62M and bringing the position to 480,249 shares worth $2.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2400.

Cliff Asness first reported a position in AARD in Q1 2026 and has held it in 2 quarters since. 72 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Cliff Asness held 480,249 shares of Aardvark Therapeutics worth $2.77M as of Q2 2026.
  • Cliff Asness bought 345,754 Aardvark Therapeutics shares in Q2 2026, an estimated $1.62M.
  • Aardvark Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2400 holding.
  • Cliff Asness first reported a position in Aardvark Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 72 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.